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Abstract B99 is a p53-inducible gene whose accumulation upon
p53 activation is restricted to late S/G2 cells. Here we have
analyzed B99 regulation during the cell cycle in murine cells with
or without functional p53. We report that B99 accumulates in
late S/G2 phase, is phosphorylated in mitosis, and disappears in
G1 phase, regardless of the status of p53. As a complement to
this observation, we show that B99 is not induced by p53 in
quiescent cells. Therefore, B99 expression is modulated both by
cell-cycle regulatory mechanisms and by p53, and p53 can
increase the cellular levels of B99 only during the window of the
cell cycle when it is normally expressed. On the basis of these
observations we rename B99 Gtse-1 (G-two- and S-phase-
expressed). ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The tumor suppressor gene p53 is one of the most frequent
targets of genetic alteration in human cancer [1]. It encodes a
short-lived transcription factor which exerts a strong antipro-
liferative activity in response to a wide spectrum of di¡erent
stimuli such as DNA damage, oncogene activation or deple-
tion of ribonucleotides [2,3]. p53 suppresses cell growth by
inducing cell-cycle arrest or apoptosis [3,4] and this activity
plays a crucial role in preventing genetic instability and cel-
lular transformation [5].
It is well established that p53 can e⁄ciently block the cell
cycle at the G1/S transition, this e¡ect being largely dependent
on induction of p21Waf1, a potent inhibitor of G1 cyclin-de-
pendent kinases [6,7]. But increasing evidence suggests that
p53 might also have an important function in controlling
cell-cycle events past the G1/S transition. In fact, p53-null
cells tend to develop an aberrant number of centrosomes
[8,9] and have a defective spindle checkpoint [10], and in sev-
eral cell lines p53 activation results in both G1 and G2 arrest
[11^13]. The importance of p21Waf1 in these activities is un-
clear [14,15] and it is likely that some other p53 target genes
might be involved [16,17].
B99 was discovered during a di¡erential screening devised
to isolate novel p53-inducible genes in a murine cell line
(Val5) expressing the temperature-sensitive Val135 mutant
p53 [18]. Upon temperature-mediated p53 activation, Val5
cells undergo a reversible cell-cycle arrest without evidence
of apoptosis [19,20] ; it is therefore reasonable to assume
that genes induced by p53 in these cells are likely to be in-
volved in establishing and maintaining a status of reversible
growth arrest. Preliminary characterization revealed that B99
encodes a novel protein localized to the microtubules, with no
signi¢cant homology to any gene in the databases. The B99
promoter contains a functional p53-responsive element and
B99 was shown to be induced by p53 under a number of
di¡erent conditions [18]. Interestingly, £ow cytometric analy-
sis revealed that p53 can induce accumulation of B99 protein
only in cells bearing a 4N DNA content, and transfection
experiments suggested that B99 overexpression delays pro-
gression through G2 phase [18]. Taken together, these data
point to B99 as an appealing candidate e¡ector for G2-speci¢c
functions of wild-type (wt) p53.
To our knowledge, B99 is the ¢rst example of a p53 target
gene induced by p53 only within a speci¢c cell-cycle window.
This G2 speci¢city of p53-dependent induction prompted us
to analyze in more detail the regulation of B99 during the cell
cycle, in the presence and in the absence of functional p53.
2. Materials and methods
2.1. Cell culture conditions and Northern blotting
Cells were routinely cultured at 37‡C in Dulbecco’s modi¢ed Ea-
gle’s medium supplemented with 10% fetal calf serum (FCS), penicillin
(100 U/ml) and streptomycin (100 Wg/ml). The cell lines NIH3T3 (wt
p53), BALB/c(10)1 (p53-null), and Val5 (temperature-sensitive p53
Val135) were previously described [25]. For Northern blotting, ap-
proximately 10 Wg of total RNA was separated on 1% agarose gels
containing 2.6% formaldehyde and transferred to nylon membranes as
described in [18]. UV treatment consisted of 10 J/m2 irradiation as
described in [18]. Mitotic cells were prepared after 16 h incubation in
the presence of 0.125 Wg/ml nocodazole. Culture medium was dis-
carded to eliminate £oating dead cells. Metaphase cells were detached
by vigorous shaking in phosphate-bu¡ered saline (PBS) supplemented
with 0.125 Wg/ml nocodazole and collected by centrifugation. Micro-
tubule-active drugs were purchased from Sigma and used at the fol-
lowing concentrations: nocodazole 0.125 Wg/ml; colcemid 0.5 Wg/ml;
paclitaxel (taxol) 1 WM.
2.2. Flow cytometry
Subcon£uent cells were harvested by trypsin treatment and ¢xed
with 70% ethanol at 320‡C. Fixed cells were washed in PBS/5%
FCS and incubated for 30 min at room temperature either with the
anti-B99 antiserum [18], or with a pre-immune rabbit serum as a
control. Immune complexes were detected by incubation for 30 min
with a FITC-conjugated goat anti-rabbit antibody (Sigma) and DNA
was stained with 25 Wg/ml propidium iodide after RNase A treatment.
Samples were analyzed on a Bryte HS £ow cytometer (Bio-Rad).
2.3. Plasmids, transfections and luciferase assays
The previously described 33.2 genomic fragment containing the B99
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 9 6 9 - 4
*Corresponding author. Fax: (39)-40-398990.
E-mail: schneide@sci.area.trieste.it
1 Present address: Department of Cell Biology, Harvard Medical
School, 240 Longwood Av., Boston, MA 02115, USA.
FEBS 24082 1-9-00
FEBS 24082 FEBS Letters 481 (2000) 57^62
promoter [18] was cloned in the promoterless pGL2-basic vector
(Promega) to generate the p33.2-LUC construct. Subcon£uent cells
were transfected with the pGL2-basic, the pGL2-promoter (Promega),
or the p33.2-LUC vectors, together with a 1/8 amount of pBABE-
Puro, using Lipofectin (Life Technologies). Transfected cells were se-
lected for about 2 weeks in 5 Wg/ml puromycin. Surviving clones from
each plate were trypsinized and pooled together. Luciferase assays
were performed using the Promega Luciferase Assay Kit according
to the manufacturer’s instructions. Luciferase activity was measured
in a Turner Design luminometer (Promega) and light values were
normalized for the protein concentration in each sample as deter-
mined by the Bradford colorimetric assay (Bio-Rad).
2.4. Immunoblotting and immunoprecipitation
For immunoblotting, cells were scraped in Laemmli bu¡er, soni-
cated, and immediately boiled. Lysates were fractionated by SDS^
PAGE and transferred to nitrocellulose membranes (Schleicher and
Schuell) using a semi-dry blotting apparatus (Bio-Rad). Detection of
B99 protein was performed in high salt conditions (5% low-fat dry
milk, 50 mM Tris^HCl pH 7.5, 1 M NaCl, 0.1% Tween-20) for 2 h at
room temperature. Other antigens were detected in standard condi-
tions. Primary antibodies were detected by incubation for 1 h with
horseradish peroxidase-conjugated secondary antibodies (Southern
Biotechnology). Blots were developed with the ECL chemilumines-
cence system (Amersham). For immunoprecipitation, cells were lysed
in bu¡er A (50 mM Tris^HCl pH 8, 200 mM NaCl, 10% glycerol, 1%
Triton X-100, 1 mM dithiothreitol, 100 mM NaF, 1 mM sodium
orthovanadate, 50 Wg/ml phenylmethylsulfonyl £uoride, and 10 Wg/
ml chymostatin, leupeptin, antipain and pepstatin), passed several
times through a 27 gauge needle, and centrifuged to remove cell de-
bris. Supernatants were preclari¢ed with protein A-Sepharose for 30
min, and incubated with MPM-2 monoclonal antibody (mitotic phos-
phoprotein monoclonal-2, kindly provided by T. Stukenberg) pre-
bound to 20 Wl of protein A-Sepharose CL-4B (Amersham Pharma-
cia) for 3 h at 4‡C with gentle agitation. Beads were washed four times
with bu¡er A, and bound proteins were eluted by boiling in Laemmli
sample bu¡er. Immunoprecipitated proteins and aliquots of the super-
natants were separated on 10% SDS^PAGE and analyzed by immu-
noblotting.
2.5. In vitro translation and incubation in Xenopus egg extracts
B99 was in vitro translated from the pCS2B99 expression vector
[21] using a coupled transcription/translation reticulocyte lysate sys-
tem (Promega) in the presence of 35S-labelled methionine. 1 Wl of in
Fig. 1. Analysis of B99 expression during the cell cycle. A: Cell-cycle regulation of B99 mRNA. NIH3T3 ¢broblasts were arrested by 48 h cul-
ture in low serum (0.5% FCS) and stimulated to re-enter the cell cycle by addition of 20% FCS. Total RNA was prepared at the indicated
time points and B99 expression was analyzed by Northern blotting. GAPDH was analyzed in the same blot as a loading control. B: Cell-cycle
regulation of B99 protein. NIH3T3 cells were treated as in A. Lysates were collected at the indicated time points and B99 expression was ana-
lyzed by immunoblotting. Cyclins A and B were analyzed in the same lysates as markers of cell-cycle progression. The growth arrest-speci¢c
protein Gas1 was analyzed as a marker of G0 [23]. C: Cell-cycle regulation of B99 is not a¡ected by microtubule-active drugs. NIH3T3 cells
were treated as in A in the absence or in the presence of microtubule-active drugs. Lysates were prepared at the indicated time points and B99
was detected by immunoblotting. Cyclin B was analyzed as a marker of G2/M. C: colcemid; N: nocodazole; T: taxol (paclitaxel). The arrow
indicates a slower-migrating form of B99 speci¢cally observed in mitotic cells. D: Bivariate £ow cytometric analysis of B99 protein and DNA
content. Subcon£uent NIH3T3 and BALB/c(10)1 cells were simultaneously stained with propidium iodide (x-axis) and either the anti-B99 or a
control antibody followed by a FITC-conjugated secondary antibody (y-axis). FITC £uorescence is plotted against DNA content. Values are
expressed on a linear scale. The line indicates the approximate cut-o¡ for B99-positive cells.
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vitro translated B99 was added to 10 Wl interphase or mitotic extract
(at room temperature) and time points were taken at 0 min and 60
min. Calf intestinal phosphatase was added at 60 min, and samples
were incubated for an additional 30 min at room temperature. Inter-
phase extracts were prepared as described [22], using calcium iono-
phore at 1 Wg/ml to activate unfertilized Xenopus eggs to complete the
second meiotic division. Cycloheximide was added at a ¢nal concen-
tration of 100 Wg/ml to inhibit further translation of B99 and to
prevent accumulation of cyclins (i.e. to maintain the interphase state
during the incubation period). Mitotic extracts were prepared by ad-
dition of 60 Wg/ml bacterially expressed sea urchin N-90 cyclin B (a
non-degradable form of cyclin) to the interphase extracts [21].
3. Results
3.1. Cell-cycle regulation of B99 mRNA and protein
B99 mRNA and protein levels were analyzed in NIH3T3
mouse ¢broblasts arrested in G0 by serum starvation and
stimulated to synchronously re-enter the cell cycle by addition
of 20% FCS [23]. As shown in Fig. 1A,B, B99 was undetect-
able in quiescent cells, accumulated during S phase (18 h), and
reached maximum levels during G2 (22 h), with kinetics very
similar to G2 cyclins. The protein expression pro¢le correlated
with expression of the mRNA. Notably, both B99 mRNA and
protein levels clearly decreased at 30 h when, although syn-
chronization is signi¢cantly loosened (see expression of cy-
clins), a large fraction of the cells are in the G1 phase of
the following cell cycle.
Since B99 protein consistently displays microtubular local-
ization [18], we asked whether its expression could be a¡ected
by the status of microtubules. B99 protein was analyzed in
NIH3T3 cells arrested in G0 by serum starvation and stimu-
lated to synchronously re-enter the cell cycle in the presence of
microtubule-active drugs. As reported in Fig. 1C, B99 protein
was regulated normally in the presence of nocodazole or col-
cemid, with a somewhat lower induction in the presence of
taxol, probably because of the higher toxicity of the drug.
Expression of B99 paralleled expression of cyclin B analyzed
in the same extracts. Therefore, expression of B99 is not sig-
ni¢cantly a¡ected by the status of the microtubules. A lower
mobility band appeared in lysates highly enriched in mitotic
cells (30 h time point); this band re£ects a post-translational
modi¢cation of B99 which is described below.
As a complement to the data obtained during cell-cycle re-
entry from quiescence, we employed £ow cytometry to ana-
lyze B99 levels during the normal cell cycle in asynchronous
proliferating cells. Subcon£uent NIH3T3 and BALB/c(10)1
¢broblasts were stained with the anti-B99 antiserum and
B99 £uorescence was plotted against DNA £uorescence as
shown in Fig. 1D. As expected, B99 £uorescence was low in
the G1 phase and peaked in the G2 phase, con¢rming the
regulation observed during cell-cycle progression from G0.
A similar pro¢le was reported for cyclin B1 in human lym-
phoblastoid cells [24]. This regulation was virtually identical
in NIH3T3, which are wild-type for p53 [25], and in BALB/
c(10)1, which are p53-null [26], indicating that such regulation
is not dependent on p53.
3.2. Cell-cycle regulation of the B99 promoter
The analysis of B99 mRNA (Fig. 1A) suggested that B99
might be transcriptionally regulated during the cell cycle. To
address this issue, a 2.6-kb genomic fragment encompassing
the promoter sequences and the ¢rst exon of B99 was cloned
upstream of ¢re£y luciferase in the pGL2-basic vector (p33.2-
LUC). This construct was co-transfected with a puromycin
resistance gene in NIH3T3 and in BALB/c(10)1 ¢broblasts.
After selection, resistant clones were pooled and luciferase
activity was measured in proliferating and quiescent cells.
As a control, pools of stable transfectants were selected con-
taining either a promoterless (pGL2-basic) or an SV40-driven
(pGL2-promoter) luciferase reporter vector. As summarized
in Fig. 2A, the B99 promoter was signi¢cantly repressed in
cells arrested either by serum starvation or by growth to con-
£uence. In contrast, expression from the SV40 promoter
underwent only minor variations. Similar results were ob-
tained in transient transfection experiments in both cell lines
(not shown). Again, although this genomic construct con-
tained a functional p53-responsive element [18], the behavior
of the B99 promoter was identical in p53-containing and in
p53-null cells, indicating that the observed regulation was not
a consequence of cell-cycle £uctuations of p53 activity.
Transcription from B99 promoter was also analyzed during
synchronous cell-cycle re-entry of serum-starved NIH3T3
(Fig. 2B). Activity of the B99 promoter was low in G1 (6 h
after serum addition) and high in G2 (22 h), thus recapitulat-
ing the observed regulation of B99 mRNA and protein.
3.3. B99 is modi¢ed by phosphorylation in mitotic cells
To analyze the regulation of B99 protein during the tran-
sition from M to G1 phase, mitotic NIH3T3 cells were accu-
Fig. 2. Cell-cycle regulation of B99 promoter. A: Polyclonal stable
transfectants containing the B99 promoter construct p33.2-LUC
were selected in NIH3T3 and BALB/c(10)1 murine ¢broblasts (33.2
A to D: two separate polyclones were obtained in each cell line).
Stable transfectants containing either the promoterless pGL2-basic
vector (Basic) or the SV40-driven pGL2-promoter vector (SV) were
selected as negative and positive controls respectively. Luciferase ac-
tivity was measured in subcon£uent growing cells (10% FCS), and
in cells arrested by 48 h serum starvation (0.5% FCS) or growth to
con£uence (DDI). Clones 33.2 A and B, as well as Basic and SV
controls, are NIH3T3 cells. Clones 33.2 C and D are BALB/c(10)1
cells. B: The indicated polyclones were growth-arrested by serum
starvation and stimulated to synchronously re-enter the cell cycle as
described in the legend to Fig. 1. Luciferase activity was measured
6 h (G1) and 22 h (G2) after serum addition.
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mulated by nocodazole treatment, collected by shake-o¡, and
re-plated in the absence of nocodazole [27]. As shown in Fig.
3A, the antibody to B99 detected in mitotic cells a protein
displaying signi¢cantly slower mobility than interphase ex-
tracts. This mitosis-speci¢c mobility shift of B99 is due to
post-translational modi¢cation, since it was also detected on
transiently transfected epitope-tagged B99 (not shown). And
this modi¢cation is not a consequence of drug treatment, since
it was also observed when mitotic cells were collected by
shake-o¡ without prior nocodazole treatment (not shown).
When metaphase cells are re-plated in the absence of nocoda-
zole, they rapidly complete mitosis and enter the G1 phase. As
shown in Fig. 3A, B99 protein disappeared within 2 h after re-
plating, con¢rming that B99 is e⁄ciently downregulated in
G1.
To understand the molecular basis of the observed mobility
shift in mitotic cells, in vitro translated B99 protein was in-
cubated in interphase or mitotic Xenopus egg extracts. As
shown in Fig. 3B, B99 protein was shifted to lower mobility
in the mitotic extract. This band migrated with approximately
the same electrophoretic mobility as the endogenous B99 pro-
tein detected in mitotic cells (see Fig. 3A). The protein re-
turned to its original mobility after treatment with phospha-
tase, implying that the shift is due to phosphorylation. Similar
results were obtained when total lysates from mitotic NIH3T3
cells were phosphatase-treated and B99 protein was analyzed
by immunoblotting (not shown).
B99 protein contains several Ser/Thr-Pro motifs; the anti-
body MPM-2 recognizes the phosphorylated Ser/Thr-Pro epi-
tope on many important regulators speci¢cally phosphorylat-
ed at mitosis [28,29]. We therefore asked whether mitotic B99
could be recognized by the MPM-2 antibody; quiescent
NIH3T3 were stimulated to re-enter the cell cycle by addition
of growth factors, nocodazole was added after 18 h, and mi-
totic phosphoproteins were immunoprecipitated with MPM-2
at 30 h post-activation. Under these conditions the interphase
and mitotic forms of B99 are both easily detected (see Fig.
1C). As shown in Fig. 3C, the MPM-2 antibody selectively
immunoprecipitated the slower-migrating, mitotic form of
B99. The interphase form of B99 was not recognized by
MPM-2 in these extracts, or in similar extracts from G2 cells
in which the mitotic form is absent. We conclude that B99 is
speci¢cally phosphorylated during mitosis to generate an
MPM-2 phosphoepitope.
3.4. B99 is not induced by p53 in quiescent cells
Since B99 mRNA and protein are dramatically induced by
p53 activation and are strictly regulated during the cell cycle,
we further investigated the correlation between cell cycle-de-
pendent and p53-dependent regulation of B99. To analyze
B99 protein levels after activation of wt p53 in conditions in
Fig. 4. p53-dependent B99 induction in cycling versus arrested cells.
A: Analysis of B99 expression after UV irradiation of NIH3T3 cells
asynchronously growing (10% FCS), or arrested by either serum
starvation (0.5% FCS) or growth to con£uence (DDI). Lysates were
prepared 18 h after UV treatment. B: Analysis of p53-dependent
regulation of B99 in Val5 cells asynchronously growing (10% FCS)
or arrested by serum starvation (0.1% FCS). For each culture condi-
tion, lysates were prepared from cells growing at 37‡C or kept for
12 h at 32‡C. p21Waf1 was analyzed in the same extracts as a con-
trol of p53 activation. Bands in di¡erent blots are not comparable
because of di¡erent exposure times required to increase the very
weak B99 signal in arrested cells.
Fig. 3. B99 phosphorylation in mitotic cells. A: Analysis of B99
during M to G1 transition. Mitotic NIH3T3 cells were collected by
shake-o¡ after nocodazole treatment (time 0) and replated in drug-
free medium for 2 h. B99 protein was analyzed by immunoblotting
together with cyclin B as a marker of G2/M. Note the altered mi-
gration of B99 in the mitotic lysate. B: Phosphorylation of B99 in
mitotic extracts. Radioactively labeled in vitro translated B99 was
incubated for 1 h in interphase (I) or mitotic (M) Xenopus egg ex-
tracts at room temperature. Where indicated, calf intestinal phos-
phatase (CIP) was added after 1 h incubation, and incubated for an
additional 30 min. C: Immunoprecipitation of mitotic B99 with the
MPM-2 antibody. NIH3T3 cells were arrested by serum starvation
and stimulated to enter the cell cycle as described in Fig. 1. Transi-
tion through mitosis was inhibited by nocodazole and cells were col-
lected 22 h or 30 h after serum stimulation. Proteins were immuno-
precipitated (IP) with the MPM-2 antibody in the presence of
phosphatase inhibitors, followed by immunoblotting with the anti-
B99 serum. Interphase and mitotic forms of B99 are indicated by
arrows.
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which B99 is not normally expressed, we tested B99 induction
after DNA damage in quiescent NIH3T3. Dividing and ar-
rested cells were exposed to UV light (10 J/m2) and lysates
were prepared 18 h after treatment. As shown in Fig. 4A, B99
protein was e⁄ciently accumulated in asynchronously grow-
ing cells. Induction of B99 was undetectable in serum-starved,
and extremely weak in density-inhibited cells. In contrast, reg-
ulation of p21Waf1, analyzed as a control, was less in£uenced
by growth conditions. It is important to note that under these
conditions UV damage to NIH3T3 cells does not increase the
G2/M subpopulation (data not shown). Anyway, it is possible
that p53 activity might £uctuate during the cell cycle [30^34],
and it has been reported that UV-induced p53 accumulation
might not occur in G0 cells, although DNA binding and se-
quence-speci¢c transactivation are still detected [31,35]. We
therefore analyzed B99 expression after activation of a tem-
perature-sensitive p53 protein (Val135) constitutively ex-
pressed at high levels in the Val5 cell line [19,36]. Val5 ¢bro-
blasts were made quiescent by prolonged culture in 0.1% FCS,
a treatment resulting in a signi¢cant decrease of S/G2 cells as
assessed by £ow cytometry (not shown). p53 was subsequently
activated by transferring the cells to the permissive temper-
ature of 32‡C and B99 expression was analyzed by immuno-
blotting 12 h later. As shown in Fig. 4B, B99 was strongly
induced after conformational activation of p53 in proliferat-
ing cells, but was very poorly induced in arrested cells. This
regulation was speci¢c, since p21Waf1 was clearly induced in
both conditions.
4. Discussion
B99 was cloned as a p53-inducible gene, its promoter con-
tains a functional p53-responsive element, and B99 protein is
e⁄ciently induced upon p53 activation by a number of diverse
stimuli, but only in cells having a 4N DNA content [18]. This
last observation prompted us to investigate whether B99
might be normally regulated during the cell cycle and how
such a regulation might be interlaced with its p53 responsive-
ness. We have now clearly demonstrated that B99 is tightly
regulated during the cell cycle, its expression beginning at
S phase and reaching maximum levels in G2. Importantly,
we have observed the same regulation for the recently cloned
human homologue of B99 (manuscript in preparation). Dur-
ing mitosis B99 is phosphorylated, and promptly disappears
as cells complete anaphase and enter G1. This regulation is
identical in wt p53-containing and p53-null murine cells. We
have shown that a genomic fragment containing the B99 pro-
moter is su⁄cient to confer cell-cycle regulation to a luciferase
reporter gene and again, we provided evidence that this reg-
ulation is uncoupled from p53 function. Detailed molecular
analysis of the promoter elements mediating cell cycle-speci¢c
transcription of B99 was beyond the aim of the present study,
but the construct we have described is a useful tool for future
analysis. In particular, it will be interesting to determine
whether any transcriptional regulatory elements are conserved
between B99 promoter and those of other cell cycle-regulated
genes such as CDC25C, Plk1, cyclin A and cyclin B1, which
share a similar pro¢le of expression [37^39].
Analysis of B99 in mitotic cells revealed that B99 is modi-
¢ed during mitosis, resulting in a large shift in electrophoretic
mobility. Although we cannot exclude additional modi¢ca-
tions, we presented data clearly indicating that B99 protein
is phosphorylated in mitotic extracts. In a number of proteins,
many of which are associated with structural components of
the mitotic apparatus, phosphorylation generates a phospho-
epitope which is speci¢cally recognized by the MPM-2 mono-
clonal antibody [28,40]. We have shown here that mitotic B99
is recognized by MPM-2, thus adding B99 to the list of mi-
totic MPM-2 phosphoepitopes. It is attractive to speculate
that such phosphorylation might regulate B99 function during
mitosis (e.g. modulating its a⁄nity for microtubules or other
protein partners), or might be targeting B99 for subsequent
destruction. These hypotheses await experimental veri¢cation
and will be the subject of future investigations.
During preparation of this article a paper was published
describing a novel APC recognition signal functionally similar
but distinct from the destruction box of mitotic cyclins [21];
this motif, named the KEN box, behaves as a targeting signal
for degradation by the Cdh1-activated form of the anaphase-
promoting complex (Cdh1-APC). Interestingly, the authors
recognized a consensus KEN sequence within the carboxy-
terminus of B99 and demonstrated that in vitro translated
B99 is e⁄ciently degraded by Cdh1-APC in Xenopus egg ex-
tracts [21]. Deletion or mutation of the KEN box protected
B99 from ubiquitination and degradation [21]. Since Cdh1-
APC assembles at late mitosis and is believed to be active
throughout the G1 phase (see [41,42] and references therein),
this observation provides a convincing explanation for the
rapid disappearance of B99 protein in post-mitotic cells (see
Fig. 3A).
Many p53-inducible genes are subject to p53-independent
regulation; although these genes are induced by p53, they
have autonomous cellular roles in the absence of p53 activa-
tion. A clear example is p21Waf1, a very important and well
studied e¡ector of p53 functions [7,43] which is normally ex-
pressed in p53-null cells, plays an autonomous and p53-inde-
pendent role in cell-cycle progression, and is regulated by a
number of di¡erent pathways in addition to p53 [44^46]. Here
we show that the same principle holds true for B99; in fact
not only is B99 normally regulated during the cell cycle in
p53-null ¢broblasts, but B99 protein was detected under pro-
liferating conditions in all murine cell lines tested so far, re-
gardless of their p53 status (L. Collavin and M. Monte, un-
published). Expressed sequence tags corresponding to B99
have been sequenced from two-cell mouse embryo (accession
number AU018143) and mouse blastocyst (accession number
AA571318) libraries, further suggesting that B99 is expressed
in most, if not all, dividing cells. Finally, similarly to
p21Waf1, B99 protein can be induced by UV treatment in
p53-null ¢broblasts [18].
We therefore conclude that B99 is a cell cycle-regulated
gene which is only expressed in S and G2 phase. Within this
window of expression, B99 levels can be dramatically in-
creased by activation of p53. We think this supports the hy-
pothesis that B99 might be involved in cell cycle-related func-
tions, or checkpoints, during late S and G2 phases. On the
basis of these observations, we propose replacing the provi-
sional name B99 with the de¢nitive name Gtse-1, acronym for
G-two- and S-phase-expressed protein.
Acknowledgements: We wish to thank Stefania Marzinotto for tech-
nical assistance. We also thank Michele Pagano, who provided the
cyclin B antiserum, and Todd Stuckenberg who provided the MPM-2
monoclonal antibody. This work was supported by grants from AIRC
and Telethon. L.C. was supported by a fellowship from the Italian
FEBS 24082 1-9-00
L. Collavin et al./FEBS Letters 481 (2000) 57^62 61
Foundation for Research on Cancer (FIRC) and M.M. by a fellow-
ship from the ICGEB.
References
[1] Hollstein, M. et al. (1994) Nucleic Acids Res. 22, 3551^3555.
[2] Ko, L.J. and Prives, C. (1996) Genes Dev. 10, 1054^1072.
[3] Hansen, R. and Oren, M. (1997) Curr. Opin. Genet. Dev. 7, 46^
51.
[4] Levine, A.J. (1997) Cell 88, 323^331.
[5] Lane, D. (1992) Nature 358, 15^16.
[6] Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R.
and Beach, D. (1993) Nature 366, 701^704.
[7] El-Deiry, W.S. et al. (1993) Cell 75, 817^825.
[8] Brown, C.R., Doxsey, S.J., White, E. and Welch, W.J. (1994)
J. Cell. Physiol. 160, 47^60.
[9] Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S. and Vande
Woude, G.F. (1996) Science 271, 1744^1747.
[10] Cross, S.M., Sanchez, C.A., Morgan, C.A., Schimke, M.K., Ra-
mel, S., Idzerda, R.L., Raskind, W.H. and Keid, B.J. (1995)
Science 267, 1353^1356.
[11] Stewart, N., Hicks, G.G., Paraskevas, F. and Mowat, M. (1995)
Oncogene 10, 109^115.
[12] Taylor, W.R., DePrimo, S.E., Agarwal, A., Agarwal, M.L.,
Schonthal, A.H., Katula, K.S. and Stark, G.R. (1999) Mol.
Biol. Cell 10, 3607^3622.
[13] Agarwal, M.L., Agarwal, A., Taylor, W. and Stark, G.R. (1995)
Proc. Natl. Acad. Sci. USA 92, 8493^8497.
[14] Deng, C., Zhang, P., Wade Harper, J., Elledge, S.J. and Leder, P.
(1995) Cell 82, 675^684.
[15] Lanni, J.S. and Jacks, T. (1998) Mol. Cell. Biol. 18, 1055^1064.
[16] Furnari, B., Rhind, N. and Russell, P. (1997) Science 277, 1495^
1497.
[17] Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L.,
Thiagalingam, S., Kinzler, K.W. and Vogelstein, B. (1997) Mol.
Cell 1, 3^11.
[18] Utrera, R., Collavin, L., Lazarevic, D., Delia, D. and Schneider,
C. (1998) EMBO J. 17, 5015^5025.
[19] Wu, X. and Levine, A.J. (1994) Proc. Natl. Acad. Sci. USA 91,
3602^3606.
[20] Del Sal, G., Murphy, M., Ruaro, E., Lazarevic, D., Levine, A.J.
and Schneider, C. (1996) Oncogene 12, 177^185.
[21] P£eger, C.M. and Kirschner, M.W. (2000) Genes Dev. 14, 655^
665.
[22] Murray, A.W. (1991) Methods Cell Biol. 36, 581^605.
[23] Del Sal, G., Ruaro, M.E., Philipson, L. and Schneider, C. (1992)
Cell 70, 595^607.
[24] Widrow, R.J., Hansen, R.S., Kawame, H., Gartler, S.M. and
Laird, C.D. (1998) Proc. Natl. Acad. Sci. USA 95, 11246^11250.
[25] Del Sal, G., Ruaro, E.M., Utrera, R., Cole, C.N., Levine, A.J.
and Schneider, C. (1995) Mol. Cell. Biol. 15, 7152^7160.
[26] Harvey, D.M. and Levine, A.J. (1991) Genes Dev. 5, 2375^2385.
[27] Brandeis, M. and Hunt, T. (1996) EMBO J. 15, 5280^5289.
[28] Davis, F.M., Tsao, T.Y., Fowler, S.K. and Rao, P.N. (1983)
Proc. Natl. Acad. Sci. USA 80, 2926^2930.
[29] Matsumoto-Taniura, N., Pirollet, F., Monroe, R., Gerace, L. and
Westendorf, J.M. (1996) Mol. Biol. Cell 7, 1455^1469.
[30] Wang, Y. and Prives, C. (1995) Nature 376, 88^91.
[31] Pitkanen, K., Haapajarvi, T. and Laiho, M. (1998) Oncogene 16,
459^469.
[32] Zhan, Q., Carrier, F. and Fornace Jr., A.J. (1993) Mol. Cell.
Biol. 13, 4242^4250.
[33] Reich, N.C. and Levine, A.J. (1984) Nature 308, 199^201.
[34] Siu, W.Y., Arooz, T. and Poon, R.Y. (1999) Exp. Cell Res. 250,
131^141.
[35] Haapajarvi, T., Pitkanen, K., Tsubari, M. and Laiho, M. (1997)
Mol. Cell. Biol. 17, 3074^3080.
[36] Martinez, J., Georgo¡, I., Martinez, J. and Levine, A.J. (1991)
Genes Dev. 5, 151^159.
[37] Uchiumi, T., Longo, D.L. and Ferris, D.K. (1997) J. Biol. Chem.
272, 9166^9174.
[38] Zwicker, J. and Muller, R. (1997) Trends Genet. 13, 3^6.
[39] Zwicker, J., Lucibello, F.C., Wolfraim, L.A., Gross, C., Truss,
M., Engeland, K. and Muller, R. (1995) EMBO J. 14, 4514^4522.
[40] Ya¡e, M.B. et al. (1997) Science 278, 1957^1960.
[41] Kramer, E.R., Scheuringer, N., Podtelejnikov, A.V., Mann, M.
and Peters, J.M. (2000) Mol. Biol. Cell 11, 1555^1569.
[42] Fang, G., Yu, H. and Kirschner, M.W. (1999) Phil. Trans. R.
Soc. Lond. B Biol. Sci. 354, 1583^1590.
[43] Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge,
S.J. (1993) Cell 75, 805^816.
[44] Loignon, M., Fetni, R., Gordon, A.J. and Drobetsky, E.A.
(1997) Cancer Res. 57, 3390^3394.
[45] Michieli, P., Chedid, M., Lin, D., Pierce, J.H., Mercer, W.E. and
Givol, D. (1994) Cancer Res. 54, 3391^3395.
[46] Bottazzi, M.E., Zhu, X., RM, B.h. and Assoian, R.K. (1999)
J. Cell Biol. 146, 1255^1264.
FEBS 24082 1-9-00
L. Collavin et al./FEBS Letters 481 (2000) 57^6262
